volinanserin

Small moleculeexperimental

Volinanserin is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor. It was also tested in clinical trials as a potential antipsychotic, antidepressant, and treatment for insomnia but was never marketed. — Wikipedia

Clinical trial activity

5 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
0

Earliest trial started Sep 1, 2003 (NCT00070694)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
Mol. weight
373.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (alpha-r)-
  • alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenylethyl))-4-piperidine methanol
  • m100907
  • m-100907
  • m-100907
  • mdl100105
  • mdl 100105
  • mdl 100907
  • mdl 100,907
  • mdl-100907
  • mdl-100907
  • mdl-100907
  • mdl-100,907
  • mdl-100.907
  • mdl-100.907
  • mdl100.907
  • mdl100.907
  • (r)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol
  • volinanserin
  • volinanserin
  • volinanserin
  • volinanserin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00788515Phase 3Nov 1, 2008Sanofi
NCT00495885Phase 3Jun 1, 2007Sanofi
NCT00464061Phase 3Apr 1, 2007Sanofi
NCT00464243Phase 3Apr 1, 2007Sanofi
NCT00070694Phase 2Sep 1, 2003National Institute of Mental Health (NIMH)
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SanofiFor profit4412007
National Institute of Mental Health (NIMH)Government1112003
2 organizations
Page 1 / 1